Related Experiment Video
Updated: Sep 15, 2025

09:36
Human Neural Organoids for Studying Brain Cancer and Neurodegenerative Diseases
Published on: June 28, 2019
10.1K
A young-onset dementia case associated with PDGFRβ mutation
Ozlem Totuk1, Nazire Çelem1, Sevki Sahin1
1University of Health Sciences, Hamidiye Faculty of Medicine, Department of Neurology, Istanbul, Türkiye.
Journal of Alzheimer'S Disease Reports
|July 14, 2025
Summary
A rare genetic variant in the PDGFRB gene may contribute to young-onset dementia (YOD). This finding offers new insights into the genetic causes of early-onset cognitive decline and vascular issues.
Area of Science:
- Neurogenetics
- Vascular Biology
- Dementia Research
Background:
- Young-onset dementia (YOD) presents before age 65 and has diverse etiologies.
- Genetic factors are increasingly recognized in the pathogenesis of YOD.
- Platelet-derived growth factor receptor beta (PDGFRβ) plays roles in vascular development and homeostasis.
Observation:
- A 40-year-old male presented with progressive memory loss and disorientation, clinically resembling Alzheimer's disease.
- Brain imaging and cerebrospinal fluid analysis supported an Alzheimer's disease diagnosis.
- Whole-exome sequencing was performed to investigate potential genetic underpinnings.
Findings:
- A heterozygous missense variant, c.1316G>A (p.Arg439Gln), was identified in the PDGFRB gene.
- This PDGFRB variant is classified as likely pathogenic.
- The identified variant suggests a potential novel genetic link to vascular dysfunction contributing to cognitive decline.
Implications:
- This case suggests PDGFRB variants as a potential cause of YOD.
- Understanding the role of PDGFRβ in vascular health may reveal new therapeutic targets for dementia.
- Further research is warranted to explore the functional consequences of PDGFRB variants in cognitive aging.
Related Concept Videos
Parkinson's Disease: Overview
715
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
715
Alzheimer's Disease: Overview
673
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
673
Parkinson's Disease: Treatment
385
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
385
Neural Regulation
40.2K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
40.2K
Alzheimer's Disease: Treatment
263
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
263

